Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPANRAY vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Serotonin-dopamine activity modulator; partial agonist at 5-HT1A and D2 receptors, antagonist at 5-HT2A receptors.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
FDA: Adjunctive treatment of schizophrenia in adults.,Off-label: Bipolar I disorder (maintenance), major depressive disorder (adjunctive), Tourette syndrome, obsessive-compulsive disorder, post-traumatic stress disorder, autism-associated irritability.
Hypertension
1.5 mg orally once daily at bedtime, titrated up to a maximum of 3 mg once daily.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Terminal elimination half-life is approximately 62 hours following oral administration, allowing for once-daily dosing.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Primarily metabolized by CYP3A4 and CYP2D6; minor pathways include CYP1A2 and CYP2C19.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Primarily hepatic metabolism via CYP1A2 and CYP3A4, with 18% excreted unchanged in urine and 26% in feces as metabolites.
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
99.5% bound to albumin and alpha-1-acid glycoprotein.
Approximately 70-80% bound to plasma proteins, primarily albumin.
Apparent Vd is 4.0 L/kg, indicating extensive tissue distribution beyond plasma volume.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral bioavailability is 30–40% due to first-pass metabolism.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use is not recommended due to lack of data.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh Class A: No dosage adjustment. Child-Pugh Class B: Reduce dose to 1 mg once daily, may increase to 1.5 mg based on tolerability. Child-Pugh Class C: Use is not recommended.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not approved for pediatric patients below 18 years of age; no specific dosing guidelines available.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Elderly patients may be more sensitive to sedative and orthostatic hypotensive effects. Initiate at 1 mg once daily, titrate cautiously. Maximum dose 1.5 mg once daily for patients >65 years.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SERPANRAY is not approved for the treatment of dementia-related psychosis.
None.
Cerebrovascular adverse events in elderly dementia patients; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); hyperprolactinemia; orthostatic hypotension; leukopenia/neutropenia/agranulocytosis; seizures; body temperature dysregulation; dysphagia; falls; cognitive and motor impairment; increased mortality in elderly with dementia.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Hypersensitivity to SERPANRAY or any of its components; concomitant use with strong CYP3A4 inducers or inhibitors (due to potential for significant drug interactions); history of severe allergic reactions (e.g., anaphylaxis, angioedema) to SERPANRAY.
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Take with food to enhance absorption. High-fat meals increase lumateperone exposure. Avoid grapefruit juice as it may increase drug levels.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
First trimester: No adequate human data; animal studies not available. Risk cannot be excluded. Second/third trimester: No data; consider risks versus benefits. Pregnancy category N (not classified by FDA due to lack of data).
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Caution recommended; consider alternative agents.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
No pharmacokinetic studies in pregnancy; dose adjustments not established. Use lowest effective dose if required. Monitor for clinical response and adverse effects.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
SERPANRAY (lumateperone) is an atypical antipsychotic with a unique receptor binding profile (5-HT2A antagonist, D2 antagonist, and SERT inhibitor). It is indicated for schizophrenia and bipolar depression. Dosing is fixed at 42 mg once daily with food. No dose titration required. Common side effects include somnolence, sedation, and dry mouth. Monitor for metabolic changes, extrapyramidal symptoms, and tardive dyskinesia. Avoid use in hepatic impairment (Child-Pugh B or C).
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take SERPANRAY exactly as prescribed once daily with food.,Do not stop taking this medicine without talking to your doctor.,This medicine may cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from a sitting or lying position to minimize dizziness.,Inform your doctor immediately if you experience muscle stiffness, fever, confusion, or uneven heartbeat.,Avoid alcohol while taking SERPANRAY.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPANRAY vs ALDOCLOR-150, answered by our medical review team.
SERPANRAY is a Antihypertensive that works by Serotonin-dopamine activity modulator; partial agonist at 5-HT1A and D2 receptors, antagonist at 5-HT2A receptors.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPANRAY and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPANRAY is: 1.5 mg orally once daily at bedtime, titrated up to a maximum of 3 mg once daily.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPANRAY and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPANRAY is classified as Category C. First trimester: No adequate human data; animal studies not available. Risk cannot be excluded. Second/third trimester: No data; consider risks versus benefits. Pregnancy category . ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.